Current Report Filing (8-k)
June 15 2022 - 9:01AM
Edgar (US Regulatory)
0000890821
false
0000890821
2022-06-13
2022-06-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 13, 2022
ENVERIC
BIOSCIENCES, INC.
(Exact
name of Registrant as specified in its charter)
Delaware |
|
001-38286 |
|
95-4484725 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(IRS
Employer
Identification
No.) |
Enveric
Biosciences, Inc.
4851
Tamiami Trail N, Suite 200
Naples,
FL 34103
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (239) 302-1707
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.01 per share |
|
ENVB |
|
The
Nasdaq Stock Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
June 13, 2022, Mike Webb and Bevin O’Neil were appointed to the board of directors (the “Board”) of Enveric Biosciences,
Inc. (the “Company”), to serve as directors of the Board for terms expiring at the 2022 annual meeting of the Company’s
stockholders, or until either of Mr. Webb or Ms. O’Neil’s successor is duly elected and qualified, or his or her earlier
death, resignation or removal. The Board has appointed Ms. O’Neil to serve on the Audit Committee of the Board and appointed Mr.
Webb to serve on the Science and Technology Committee of the Board.
There
are no arrangements or understandings between either Mr. Webb or Ms. O’Neil and any other persons pursuant to which Mr. Webb or
Ms. O’Neil were selected to serve as directors the Company. In addition, there are no transactions between the Company and either
Mr. Webb or Ms. O’Neil or his or her immediate family members requiring disclosure under Item 404(a) of Regulation S-K promulgated
under the Securities Act of 1933, as amended.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ENVERIC
BIOSCIENCES INC. |
|
|
|
Date:
June 15, 2022 |
By:
|
/s/
Joseph Tucker |
|
Name: |
Joseph
Tucker, PhD |
|
Title: |
Chief
Executive Officer |
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ameri (NASDAQ:AMRH)
Historical Stock Chart
From Sep 2023 to Sep 2024